146 related articles for article (PubMed ID: 35194718)
21. Evaluation of Influence of Various Polymers on Dissolution and Phase Behavior of Carbamazepine-Succinic Acid Cocrystal in Matrix Tablets.
Ullah M; Ullah H; Murtaza G; Mahmood Q; Hussain I
Biomed Res Int; 2015; 2015():870656. PubMed ID: 26380301
[TBL] [Abstract][Full Text] [Related]
22. Mechanistic Analysis of Cocrystal Dissolution as a Function of pH and Micellar Solubilization.
Cao F; Amidon GL; Rodriguez-Hornedo N; Amidon GE
Mol Pharm; 2016 Mar; 13(3):1030-46. PubMed ID: 26877267
[TBL] [Abstract][Full Text] [Related]
23. Application of HPMC HME polymer as hot melt extrusion carrier in carbamazepine solid dispersion.
Wu H; Liu Y; Ci T; Ke X
Drug Dev Ind Pharm; 2020 Dec; 46(12):1911-1918. PubMed ID: 32942902
[TBL] [Abstract][Full Text] [Related]
24. Effect of Surfactants and Polymers on the Dissolution Behavior of Supersaturable Tecovirimat-4-Hydroxybenzoic Acid Cocrystals.
Feng Y; Meng Y; Tan F; Lv L; Li Z; Wang Y; Yang Y; Gong W; Yang M
Pharmaceutics; 2021 Oct; 13(11):. PubMed ID: 34834187
[TBL] [Abstract][Full Text] [Related]
25. Influence of polymorphic form, morphology, and excipient interactions on the dissolution of carbamazepine compacts.
Tian F; Sandler N; Aaltonen J; Lang C; Saville DJ; Gordon KC; Strachan CJ; Rantanen J; Rades T
J Pharm Sci; 2007 Mar; 96(3):584-94. PubMed ID: 17080412
[TBL] [Abstract][Full Text] [Related]
26. Expedited Tablet Formulation Development of a Highly Soluble Carbamazepine Cocrystal Enabled by Precipitation Inhibition in Diffusion Layer.
Yamashita H; Sun CC
Pharm Res; 2019 Apr; 36(6):90. PubMed ID: 31016440
[TBL] [Abstract][Full Text] [Related]
27. The role of pH and dose/solubility ratio on cocrystal dissolution, drug supersaturation and precipitation.
Machado TC; Kuminek G; Cardoso SG; Rodríguez-Hornedo N
Eur J Pharm Sci; 2020 Sep; 152():105422. PubMed ID: 32531350
[TBL] [Abstract][Full Text] [Related]
28. Amorphous is not always better-A dissolution study on solid state forms of carbamazepine.
Jensen LG; Skautrup FB; Müllertz A; Abrahamsson B; Rades T; Priemel PA
Int J Pharm; 2017 Apr; 522(1-2):74-79. PubMed ID: 28263832
[TBL] [Abstract][Full Text] [Related]
29. Mechanistic Basis of Cocrystal Dissolution Advantage.
Cao F; Amidon GL; Rodríguez-Hornedo N; Amidon GE
J Pharm Sci; 2018 Jan; 107(1):380-389. PubMed ID: 28989017
[TBL] [Abstract][Full Text] [Related]
30. Effect of surface modification on hydration kinetics of carbamazepine anhydrate using isothermal microcalorimetry.
Otsuka M; Ishii M; Matsuda Y
AAPS PharmSciTech; 2003; 4(1):E5. PubMed ID: 12916915
[TBL] [Abstract][Full Text] [Related]
31. Influence of Drug-Polymer Interactions on Dissolution of Thermodynamically Highly Unstable Cocrystal.
Jasani MS; Kale DP; Singh IP; Bansal AK
Mol Pharm; 2019 Jan; 16(1):151-164. PubMed ID: 30482019
[TBL] [Abstract][Full Text] [Related]
32. Improving the chemical stability of amorphous solid dispersion with cocrystal technique by hot melt extrusion.
Liu X; Lu M; Guo Z; Huang L; Feng X; Wu C
Pharm Res; 2012 Mar; 29(3):806-17. PubMed ID: 22009589
[TBL] [Abstract][Full Text] [Related]
33. Insight into Flufenamic Acid Cocrystal Dissolution in the Presence of a Polymer in Solution: from Single Crystal to Powder Dissolution.
Guo M; Wang K; Qiao N; Fábián L; Sadiq G; Li M
Mol Pharm; 2017 Dec; 14(12):4583-4596. PubMed ID: 29091446
[TBL] [Abstract][Full Text] [Related]
34. Explaining dissolution properties of rivaroxaban cocrystals.
Hriňová E; Skořepová E; Čerňa I; Královičová J; Kozlík P; Křížek T; Roušarová J; Ryšánek P; Šíma M; Slanař O; Šoóš M
Int J Pharm; 2022 Jun; 622():121854. PubMed ID: 35623488
[TBL] [Abstract][Full Text] [Related]
35. Dissolution Advantage of Nitazoxanide Cocrystals in the Presence of Cellulosic Polymers.
Salas-Zúñiga R; Rodríguez-Ruiz C; Höpfl H; Morales-Rojas H; Sánchez-Guadarrama O; Rodríguez-Cuamatzi P; Herrera-Ruiz D
Pharmaceutics; 2019 Dec; 12(1):. PubMed ID: 31881696
[TBL] [Abstract][Full Text] [Related]
36. Initial dissolution kinetics of cocrystal of carbamazepine with nicotinamide.
Hattori Y; Sato M; Otsuka M
J Pharm Pharmacol; 2015 Nov; 67(11):1512-8. PubMed ID: 26285918
[TBL] [Abstract][Full Text] [Related]
37. Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder.
Murphy D; Rodríguez-Cintrón F; Langevin B; Kelly RC; Rodríguez-Hornedo N
Int J Pharm; 2002 Oct; 246(1-2):121-34. PubMed ID: 12270615
[TBL] [Abstract][Full Text] [Related]
38. Towards a universal dissolution medium for carbamazepine.
El-Massik MA; Abdallah OY; Galal S; Daabis NA
Drug Dev Ind Pharm; 2006 Aug; 32(7):893-905. PubMed ID: 16908426
[TBL] [Abstract][Full Text] [Related]
39. Formation Thermodynamics of Carbamazepine with Benzamide, Para-Hydroxybenzamide and Isonicotinamide Cocrystals: Experimental and Theoretical Study.
Manin AN; Boycov DE; Simonova OR; Volkova TV; Churakov AV; Perlovich GL
Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145629
[TBL] [Abstract][Full Text] [Related]
40. pH-dependent solubility of indomethacin-saccharin and carbamazepine-saccharin cocrystals in aqueous media.
Alhalaweh A; Roy L; Rodríguez-Hornedo N; Velaga SP
Mol Pharm; 2012 Sep; 9(9):2605-12. PubMed ID: 22867056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
